Diamino Pyridine Derivatives for JAK Isoform Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current JAK modulators are inadequate for treating a wide range of diseases and disorders associated with dysregulated immune system signaling, including autoimmune and inflammatory conditions, as they lack specificity and efficacy in modulating Janus kinase activity.
Innovation Solution
Development of novel diamino pyridine derivatives that act as JAK modulators, specifically targeting JAK kinases to treat various diseases and disorders by forming pharmaceutical compositions that can be administered to provide therapeutic benefits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current JAK modulators are used to treat immune-related diseases, then therapeutic coverage is provided, but specificity and efficacy in modulating JAK activity are insufficient
Solution Approach 1:
The patent applies local quality by introducing specific substituent patterns at defined positions on the pyridine core (positions 2, 4, and 6). The core structure features specific functional groups: an amide group at position 4 with N-aryl substitution, and amino groups at positions 2 and 6 with specific substitution patterns. This localized functional group arrangement at specific positions provides both the reliability for JAK modulation and the specificity for different JAK isoforms, resolving the contradiction between general efficacy and targeted specificity.
2Adaptability or versatility
If broad-spectrum JAK inhibition is achieved, then multiple disease indications are covered, but lack of targeted modulation reduces therapeutic precision
Solution Approach 1:
The patent applies segmentation by dividing the JAK kinase family into distinct isoforms (JAK1, JAK2, JAK3, TYK2) and designing compounds with selective affinity for specific isoforms. The segmented approach involves creating series of compounds where systematic variations in substituents (R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12) enable differential binding to different JAK isoforms. This allows the same core pyridine structure to be segmented into isoform-specific modulators, achieving both broad disease coverage across multiple indications and precise modulation of specific JAK isoforms involved in different disease pathways.
Data Source
AI summary
The present invention describes novel diamino pyridine derivatives exhibiting JAK modulating properties. The present invention also relates to pharmaceutical compositions comprising these novel compounds, methods of using said compounds in the treatment of various diseases and disorders being susceptible to JAK modulation, and processes for preparing the compounds described hereinafter.